Isomorphic Labs, a UK biotech spinout of Google DeepMind, is preparing to start human clinical trials for AI-designed drugs, marking a major milestone in AI-driven drug discovery.

The platform builds on AlphaFold’s breakthroughs, which predicted structures for nearly all known proteins and contributed to Nobel Prize recognition for Hassabis and Jumper in 2024.

Looking ahead, experts foresee AGI emerging around 2030, with the job market shifting toward AI oversight and new roles, while monetization centers on licensing and consulting tied to capabilities like AlphaFold, all within strong ethical and governance frameworks.

From early algorithms to multimodal, large-scale systems like Gemini, the field has evolved into technology powering energy, climate, and healthcare, with competition among major players such as Microsoft and IBM.

DeepMind’s progress—from AlphaGo to AlphaFold—demonstrates translating reinforcement learning and large-scale modeling into real-world impact, notably in protein folding and materials science, with significant implications for faster R&D and lower discovery costs.

Hassabis’s early insight that software could act on our behalf began in 1988 with an Othello program on an Amiga 500, a moment that shaped the belief in AI working for humans and laid groundwork for DeepMind’s AGI ambitions.

Hassabis notes that AI-designed molecules can be potent at lower doses with fewer side effects and off-target interactions, aiming for safer, more effective therapies.

Isomorphic Labs leverages AlphaFold and AlphaFold 3, while introducing a newer proprietary engine called IsoDDE that reportedly doubles AlphaFold 3’s accuracy.

DeepMind’s 2014 acquisition by Google for about 400 million pounds and AlphaGo’s 2016 Go victory illustrate a trajectory toward AGI-enabled decision-making across industries.

AlphaFold, released in 2020 with over 90% accuracy, accelerated pharmaceutical R&D and reduced costs/time for firms like Pfizer and Novartis, underpinning broader biotech adoption of AI tools.

DeepMind’s strategy fuses frontier model research with mission-driven applications, signaling near-term opportunities for enterprises to integrate reinforcement learning and foundation models in domains with heavy simulations like drug discovery and climate modeling.

Isomorphic Labs secured $600 million in its first funding round, named a chief medical officer, and announced imminent clinical trials after originally aiming for 2025.